Replies to post #198384 on Biotech Values

[exwannabe]

Re: DCTH

I guess they are up because they published the results of the P3 trial that the FDA trashed 3 years ago?

The company is a joke. They have a medical device with no real IP that any BP could clone in no time. It is approved in the EU and has been on the market for something like 4 years, about $1M/year revenue.

Since discussion of DCTH does not otherwise belong on this board, I will bring up one issue that qualifies. They still hype the "OS in the crossover group" data.

This is pure BS. The crossover population is perforce selecting patients who live longer. They must be healthy after heptic progression. Crossing over to a placebo would certainly have shown the same OS benefit.